Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 1,320,709 |
|
|||||
| News | - | ||||||
| Day High | 196.36 | Low High |
|||||
| Day Low | 192.01 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -2.99 | -1.53% | 192.16 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 196.36 | 192.01 | 196.36 | 192.16 | 195.15 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 28,797 | 1,320,709 | $ 193.85 | $ 256,013,681 | - | 192.01 - 319.76 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:53:46 | 45 | $ 193.60 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 27.93B | 145.36M | - | 9.84B | 1.16B | 7.99 | 24.06 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Biogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 203.985 | 205.24 | 192.01 | 199.04 | 1,026,708 | -11.83 | -5.80% |
| 1 Month | 217.20 | 221.74 | 192.01 | 208.95 | 1,062,146 | -25.04 | -11.53% |
| 3 Months | 248.34 | 251.99 | 192.01 | 221.92 | 1,174,298 | -56.18 | -22.62% |
| 6 Months | 268.11 | 269.4312 | 192.01 | 233.80 | 1,138,831 | -75.95 | -28.33% |
| 1 Year | 294.00 | 319.76 | 192.01 | 256.47 | 1,081,333 | -101.84 | -34.64% |
| 3 Years | 269.55 | 468.2499 | 187.16 | 266.85 | 1,227,781 | -77.39 | -28.71% |
| 5 Years | 229.77 | 468.2499 | 187.16 | 269.72 | 1,385,880 | -37.61 | -16.37% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
